MX351092B - Analogos peptidicos para tratar enfermedades y trastornos. - Google Patents
Analogos peptidicos para tratar enfermedades y trastornos.Info
- Publication number
- MX351092B MX351092B MX2014005265A MX2014005265A MX351092B MX 351092 B MX351092 B MX 351092B MX 2014005265 A MX2014005265 A MX 2014005265A MX 2014005265 A MX2014005265 A MX 2014005265A MX 351092 B MX351092 B MX 351092B
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- reducing
- disorders
- treating diseases
- peptide analogs
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 210000002966 serum Anatomy 0.000 abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 238000007446 glucose tolerance test Methods 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161554771P | 2011-11-02 | 2011-11-02 | |
| US201161578620P | 2011-12-21 | 2011-12-21 | |
| US13/667,578 US9006172B2 (en) | 2011-11-02 | 2012-11-02 | Peptide analogs for treating diseases and disorders |
| PCT/US2012/063332 WO2013067357A1 (en) | 2011-11-02 | 2012-11-02 | Peptide analogs for treating diseases and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014005265A MX2014005265A (es) | 2014-10-13 |
| MX351092B true MX351092B (es) | 2017-10-02 |
Family
ID=48192827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005265A MX351092B (es) | 2011-11-02 | 2012-11-02 | Analogos peptidicos para tratar enfermedades y trastornos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9006172B2 (enExample) |
| JP (3) | JP6170933B2 (enExample) |
| KR (1) | KR102019911B1 (enExample) |
| CN (1) | CN103998052B (enExample) |
| AU (2) | AU2012332265B2 (enExample) |
| BR (1) | BR112014010701A2 (enExample) |
| CA (1) | CA2854175A1 (enExample) |
| MX (1) | MX351092B (enExample) |
| RU (1) | RU2616511C2 (enExample) |
| WO (1) | WO2013067357A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9533022B2 (en) * | 2011-11-02 | 2017-01-03 | KeyBioscience A/S | Peptide analogs for treating diseases and disorders |
| JP6639389B2 (ja) | 2013-11-14 | 2020-02-05 | キーバイオサイエンス・アクチエンゲゼルシャフト | 疾患および障害を処置するためのカルシトニン模倣体 |
| GB201500263D0 (en) * | 2015-01-08 | 2015-02-25 | Keybioscience Ag | Calcitonin analogues for treating diseases and disorders |
| GB201704429D0 (en) | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| GB201707955D0 (en) | 2017-05-18 | 2017-07-05 | Keybioscience Ag | Dual amylin and calcitonin receptor agonists for treating diseases and disorders |
| GB201813677D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| GB201813678D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
| US11420525B2 (en) | 2020-04-21 | 2022-08-23 | Mac LTT, Inc. | Tractor trailer with included battery charging |
| US12415457B2 (en) | 2020-04-21 | 2025-09-16 | Mac LTT, Inc. | Safety zone with breakaway for use on a tanker truck |
| US11634095B2 (en) | 2020-04-21 | 2023-04-25 | Mac LTT, Inc. | Removable safety bar for creating a remote safety visual device |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6033478B2 (ja) * | 1980-06-20 | 1985-08-02 | 帝国臓器製薬株式会社 | ペプチドの製造方法 |
| US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| US4659804A (en) * | 1984-11-01 | 1987-04-21 | Armour Pharmaceutical Company | (Bis-1,7-S-acetamidomethyl-L-cysteine)salmon calcitonin |
| US4764589A (en) * | 1987-05-26 | 1988-08-16 | Rorer Pharmaceutical Corporation | [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin |
| US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
| US5175146A (en) | 1989-12-05 | 1992-12-29 | Vical, Inc. | Synthetic calcitonin peptides |
| US5102666A (en) | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
| US5527790A (en) | 1991-09-30 | 1996-06-18 | The University Of British Columbia | Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| JPH083196A (ja) | 1994-06-21 | 1996-01-09 | Sanwa Kagaku Kenkyusho Co Ltd | カルシトニン誘導体及びその用途 |
| EP0726075A1 (en) | 1995-02-08 | 1996-08-14 | Therapicon Srl | Pharmaceutical non-inorganic saline solutions for endonasal administration |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5739106A (en) | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| US6174887B1 (en) | 1995-08-22 | 2001-01-16 | Japan Tobacco Inc. | Amide compounds and use of the same |
| US5962270A (en) * | 1996-02-06 | 1999-10-05 | Bionebraska, Inc. | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6103495A (en) | 1997-04-16 | 2000-08-15 | Unigene Laboratories, Inc. | Direct expression of peptides into culture media |
| CN1105726C (zh) * | 1998-05-15 | 2003-04-16 | 中国科学院上海生物化学研究所 | 人降钙素类似物 |
| JP2002531518A (ja) | 1998-12-04 | 2002-09-24 | プロヴァリス・ユーケー・リミテッド | インスリン含有医薬組成物 |
| JP2000290295A (ja) | 1999-03-31 | 2000-10-17 | Asahi Chem Ind Co Ltd | Ｎ−アセチルグルコサミニルカルシトニン |
| EP1175390B1 (en) | 1999-04-05 | 2005-02-02 | Emisphere Technologies, Inc. | Disodium salts, monohydrates, and ethanol solvates |
| US6780846B1 (en) | 1999-09-27 | 2004-08-24 | Elan Corporation, Plc | Membrane translocating peptide drug delivery system |
| GB2368792A (en) | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| US7316819B2 (en) | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
| GB0109438D0 (en) * | 2001-04-17 | 2001-06-06 | Isis Innovation | Peptides |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| CA2520660C (en) | 2003-03-28 | 2013-08-20 | Sigmoid Biotechnologies Limited | Solid oral dosage form containing seamless microcapsules |
| GB0308732D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
| US7749954B2 (en) | 2003-07-23 | 2010-07-06 | Novartis Ag | Use of calcitonin in osteoarthritis |
| JP2007523050A (ja) | 2003-09-17 | 2007-08-16 | カイアズマ・リミテッド | 生物学的障壁を通した透過を容易にすることのできる組成物 |
| BRPI0507623A (pt) | 2004-02-11 | 2007-07-03 | Amylin Pharmaceuticals Inc | peptìdeos da famìlia da amilina e métodos para prepará-los e empregá-los |
| US7399744B2 (en) | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| AU2005263729B2 (en) | 2004-07-22 | 2011-01-06 | Bey Pharma GmbH | Use of compounds containing thiol groups as an efflux pump inhibitor |
| GB0422644D0 (en) * | 2004-10-12 | 2004-11-10 | Novartis Ag | Organic compounds |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| US7445911B2 (en) | 2004-11-24 | 2008-11-04 | Unigene Laboratories Inc. | Enzymatic reactions in the presence of keto acids |
| AU2006261909B2 (en) | 2005-06-24 | 2011-08-11 | Enteris Biopharma, Inc. | Cell lines for expressing enzyme useful in the preparation of amidated products |
| JP5222727B2 (ja) | 2005-09-06 | 2013-06-26 | オーラメッド・ファーマスーティカルズ・インコーポレイテッド | タンパク質を経口投与するための方法及び組成物 |
| US8093207B2 (en) | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
| ES2369244T3 (es) | 2006-03-13 | 2011-11-28 | Advancell Advanced In Vitro Cell Technologies,S.A. | Sistemas estables de nanocápsulas para la administración de moléculas activas. |
| WO2007117706A2 (en) | 2006-04-07 | 2007-10-18 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| EP2389388B1 (en) * | 2009-01-22 | 2017-03-08 | KeyBioscience AG | Treatment for obesity |
| BRPI1009392A2 (pt) | 2009-03-12 | 2016-03-08 | Nordic Bioscience As | "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." |
-
2012
- 2012-11-02 MX MX2014005265A patent/MX351092B/es active IP Right Grant
- 2012-11-02 RU RU2014122171A patent/RU2616511C2/ru not_active IP Right Cessation
- 2012-11-02 WO PCT/US2012/063332 patent/WO2013067357A1/en not_active Ceased
- 2012-11-02 CA CA2854175A patent/CA2854175A1/en not_active Abandoned
- 2012-11-02 US US13/667,578 patent/US9006172B2/en not_active Expired - Fee Related
- 2012-11-02 JP JP2014540139A patent/JP6170933B2/ja not_active Expired - Fee Related
- 2012-11-02 KR KR1020147014281A patent/KR102019911B1/ko not_active Expired - Fee Related
- 2012-11-02 BR BR112014010701-7A patent/BR112014010701A2/pt not_active IP Right Cessation
- 2012-11-02 CN CN201280062729.0A patent/CN103998052B/zh not_active Expired - Fee Related
- 2012-11-02 AU AU2012332265A patent/AU2012332265B2/en not_active Ceased
-
2016
- 2016-10-21 AU AU2016247189A patent/AU2016247189B2/en not_active Ceased
- 2016-11-04 JP JP2016216389A patent/JP6330013B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-20 JP JP2018081153A patent/JP6547034B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6170933B2 (ja) | 2017-07-26 |
| RU2014122171A (ru) | 2015-12-10 |
| US20130183385A1 (en) | 2013-07-18 |
| AU2012332265B2 (en) | 2016-11-10 |
| JP2018135360A (ja) | 2018-08-30 |
| AU2012332265A1 (en) | 2014-06-05 |
| JP6330013B2 (ja) | 2018-05-23 |
| AU2016247189A1 (en) | 2016-11-10 |
| AU2016247189B2 (en) | 2017-09-14 |
| JP2014532722A (ja) | 2014-12-08 |
| KR20140093967A (ko) | 2014-07-29 |
| KR102019911B1 (ko) | 2019-09-09 |
| JP6547034B2 (ja) | 2019-07-17 |
| WO2013067357A1 (en) | 2013-05-10 |
| CN103998052A (zh) | 2014-08-20 |
| MX2014005265A (es) | 2014-10-13 |
| NZ625215A (en) | 2016-04-29 |
| CN103998052B (zh) | 2016-08-17 |
| US9006172B2 (en) | 2015-04-14 |
| BR112014010701A2 (pt) | 2020-06-23 |
| JP2017061500A (ja) | 2017-03-30 |
| CA2854175A1 (en) | 2013-05-10 |
| RU2616511C2 (ru) | 2017-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX351092B (es) | Analogos peptidicos para tratar enfermedades y trastornos. | |
| PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| PH12018501424B1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| MY176863A (en) | Ibat inhibitors for treatment of metabolic disorders and related conditions | |
| WO2013186240A3 (en) | Exendin-4 peptide analogues | |
| MX2013010342A (es) | Uso de dosis bajas de il-2 para tratar transtornos inflamatorios o relacionados con la autoinmunidad. | |
| NZ596037A (en) | Fgf21 mutants and uses thereof | |
| TN2013000309A1 (en) | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents | |
| NZ610034A (en) | Prevention of adverse effects caused by cd3 specific binding domains | |
| MX2016013248A (es) | Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4. | |
| BR112014006587A2 (pt) | modulação antisense da expressão de gcgr | |
| PH12015502102A1 (en) | Reducing proinflammatory response | |
| NZ595021A (en) | Treatment of diabetes and metabolic syndrome with enteral formulations of calcitonin peptides or calcitonin receptor agonists | |
| BR112013018782A2 (pt) | compostos e seus efeitos no comportamento alimentar | |
| WO2015063081A3 (en) | Micrornas modulating the effect of glucocorticoid signaling | |
| PH12016500705B1 (en) | Calcitonin mimetics for treating diseases and disorders | |
| WO2013003449A3 (en) | Methods of treatment with glp-1 receptor agonists | |
| MX2014005351A (es) | Conjugados de gastrina peptidicos de agonistas de receptor glp-1. | |
| MX353301B (es) | Composiciones tripeptidicas y metodos para tratamiento de diabetes. | |
| RU2013122841A (ru) | Лечение метаболического синдрома, диабета ii типа, ожирения или преддиабета | |
| PH12015502100A1 (en) | Reducing the risk of autoimmune disease | |
| WO2020009740A3 (en) | Compositions and methods of use thereof for treatment of metabolic diseases and related disorders | |
| PH12014502802A1 (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
| AU2010353685A8 (en) | Novel glucagon like peptide analogs, composition, and method of use | |
| MX2014003883A (es) | Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |